Long-term survival for COPD patients receiving noninvasive ventilation for acute respiratory failure by Titlestad, Ingrid L et al.
© 2013 Titlestad et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
International Journal of COPD 2013:8 215–219
International Journal of COPD
Long-term survival for COPD patients receiving 
noninvasive ventilation for acute respiratory failure
Ingrid L Titlestad1
Annmarie T Lassen2
Jørgen Vestbo1,3
1Department of Respiratory 
Medicine, 2Department of Emergency 
Medicine, Odense University Hospital, 
University of Southern Denmark, 
Odense, Denmark; 3Respiratory 
Research Group, Manchester 
Academic Health Sciences Centre, 
University Hospital South Manchester 
NHS Foundation Trust, University of 
Manchester, Manchester, UK
Correspondence: Ingrid Louise Titlestad 
Department of Respiratory Medicine, 
Odense University Hospital,  
Sdr Boulevard 29, 5000 Odense C, 
Denmark 
Email ingrid.titlestad@rsyd.dk
Abstract: Implementation of noninvasive ventilation (NIV) as an add-on treatment has been 
routinely used in a non-intensive care setting since 2004 for patients with chronic obstructive 
pulmonary disease (COPD) and acute hypercapnic respiratory failure at a university hospital 
in Denmark. Although randomized controlled trials show lowered mortality rates in highly 
selected patients with acute exacerbation and respiratory failure, there are only few reports 
on long-term survival after receiving NIV. We present long-term all-cause mortality data from 
patients receiving NIV for the first time.
Method: Data from medical records were retrospectively retrieved from all patients receiving 
NIV for the first time after being admitted acutely to an acute medical ward and further transfer 
to a respiratory ward with respiratory failure and a diagnosis of COPD in the period January 1, 
2005 to December 31, 2007; patients were followed until January 2012. Demographic data 
 collected included age, sex, diagnoses at discharge, and, when present, FEV
1
; a “not-to-intubate” 
order was also registered when listed.
Results: In total, 253 patients (143 female, 110 male) received NIV for the first time. The 
median age was 72 years (range 46–91 years). The 30-day mortality rate was 29.3%. The 5-year 
survival rate was 23.7%. Women showed a trend towards better survival than men (25.7% vs 
19.2%, P = 0.25), and the trend was even more pronounced for patients with COPD.
Conclusion: The mortality rate of patients receiving NIV is high, as expected in a real-life 
setting, but with a 5-year survival rate of 23.7% with a trend towards more female than male 
long-term survivors.
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Introduction
Randomized controlled studies have shown that noninvasive ventilation (NIV) reduces 
short-term mortality, risk of intubation and complication rate when given as an addi-
tional treatment to selected patients with an acute exacerbation in chronic obstructive 
pulmonary disease (COPD) complicated by hypercapnic acute respiratory failure.1,2 
Plant et al2 showed a decrease of the in-hospital mortality rate from 20% to 10% when 
NIV was given to patients with mild acidosis and in a stationary or intermediary ward 
in a multicenter setting. As with most other treatment modalities, there is likely to be 
a less noticeable effect when comparing real-life and clinical trial efficacy. This was 
documented in an audit performed in the UK,3 where the aim was to explore factors 
related to reported high mortality rates.
NIV was implemented as an add-on modality in an acute medical ward and a respi-
ratory ward at Odense University Hospital, Odense, Denmark, in 2004,4 based on local 
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instructions and national recommendations,5 and the modality 
has since been used as a standard additional treatment pri-
marily for patients with hypercapnic acute respiratory failure 
and verified or presumed COPD. Specifically, patients with 
arterial measures of pH , 7.35 and PaCO
2
 . 6.0 kPa and 
mono-organic symptoms of dyspnea, respiratory rate . 25 
and PaO
2
 , 7.0 kPa without oxygen therapy are eligible 
for NIV. Exclusion criteria for NIV treatment in the ward 
are untreated pneumothorax, unstable hemodynamics, and 
affected alertness, indicating need of intensified monitoring 
and intubation capability when required.
There are few reports on long-term survival after receiv-
ing NIV in a clinical setting,6 and the issue of whether there 
is an advantage by implementing NIV in patients with severe 
prognosis and expected high mortality rates has not been 
addressed. The aim of this study was to analyze long-term 
all-cause mortality following the first years of implementing 
NIV in a real-life acute medical ward at a university hospital 
in Denmark, with the null hypothesis that NIV has no impact 
on long-term survival.
Methods
All NIV treatments were registered prospectively at the 
acute medical and respiratory ward of the Odense University 
 Hospital, with patients receiving NIV for the first time in the 
period January 1, 2005 to December 31, 2007 included for 
this analysis. Data was retrospectively retrieved from medical 
records. Baseline data registered were age, sex, when regis-
tered in the records, arterial blood gas analyses initiating the 
indication for NIV (pH and pCO
2
 are presented), diagnoses at 
discharge, and forced expiratory volume in 1 second (FEV
1
). 
Lastly, a “not-to-intubate” order was also registered when listed. 
Patients were included at the time of their first NIV episode, and 
were followed until death or January 31, 2012 using the Danish 
Central Person Register to ensure complete follow-up.
Organization of ward
Patients were admitted to the acute medical ward from 
either the general practitioner or the emergency ward at 
the hospital. When patients were suspected of having an 
acute exacerbation of COPD based on clinical presentation, 
prior records, arterial blood gas analyses, and chest X-ray, 
patients were assessed after initial standard treatment with 
oxygen, inhaled bronchodilator treatment, administration of 
systemic steroids, and, if needed, antibiotics. Patients either 
continued standard medical treatment or were provided 
additional ventilatory support with NIV in the medical acute 
ward. Criteria for NIV were: (1) arterial blood pH , 7.35; 
(2) PaO
2
 , 7.0 kPa; and (3) PaCO
2
 . 6.0 kPa in patients 
with mono-organic symptoms of dyspnea and respiratory 
rate . 25. Where possible, patients initiated on NIV were 
referred to the respiratory ward the next day. Since NIV 
was initiated in the acute medical ward, standard NIV 
protocols were followed (initial inspiratory positive airway 
pressure 10 cm H
2
0 and expiratory positive airway pressure 
4cm H
2
0), with oxygen supplement depending on response 
(aim: peripheral oxygen saturation measure of 90%–92%), 
and changes in pressure were performed depending on the 
clinical manifestation in accordance with the Danish national 
guideline.5 The protocol on use of NIV remained unchanged 
in the period of the study. Initiation was done by internal 
medical staff and a respiratory physician was available for 
consultation if required.
Patients were monitored with repeated arterial analyses; 
if the patient’s status deteriorated, this patient was discussed 
with the attending intensive care unit (ICU) doctor, unless 
the patient did not want ICU treatment or the attending 
acute medical physician or respiratory physician had issued 
a “do-not-intubate” order, based on the severity of the 
underlying illness(es). On a few occasions, NIV was initi-
ated for weaning in patients with prior longer intubation 
need due to respiratory failure; these patients are reported 
on separately.
Results
In the study period 2005–2007, NIV was initiated on 390 occa-
sions: 107 times in 2005, 143 times in 2006, and 140 times 
in 2007. Of the 302 patients registered, 253 patients received 
NIV for the first time and were included in this study. Of these, 
13 patients received NIV as part of a weaning strategy.
COPD was listed as the primary diagnosis in 216 patients 
(85.4%); the diagnosis was confirmed by documented 
spirometry in 182 patients (8%) and was judged as highly 
probable in 34 patients (16%). Other diagnoses registered 
at discharge in patients presenting with acute hypercapnic 
respiratory failure were congestive heart failure, thoracic 
malignancy, and hypoventilation by other causes (see Table 1). 
Discharge diagnoses and baseline characteristics are provided 
in Table 1.
Arterial gas analyses resulting in initiation of NIV was 
registered in 51.4% of cases; in these patients, the median 
pH was 7.24 (7.07–7.43), and median pCO
2
 (kPa) was 10.1 
(6.0, 20.3).
The 30-day mortality rate for the whole group was 29.3%. 
After 5 years, 23.7% of the patients were still alive as shown 
in Figure 1. For patients with documented COPD, the cor-
responding 30-day mortality was 24.3% and 5-year survival 
was 23.1% (see Figure 2). There was no statistically significant 
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Table 1 Demographics on all patients receiving NIV for the first time at a university hospital in Denmark in 2005–2007
Nonsurvivors 
Time to death (days) 
183 (0; 13; 774; 2224)*
Survivors 
Observation time (days) 
2155 (1369; 1782; 2441; 3017)*
Patients, n (male/female) 198 (90/108) 55 (19/36)
Age (years)* 74 (46; 67; 80; 90) 66 (24; 58; 72.5; 91)**
COPD confirmed/+probable, n (%) 135/169 (68.2/85.4) 47 (85.5)
Documented spirometry, n (%) 112 (83.0)*** 32 (68.1)***
FEV1% of expected (median)* 27 (8; 19; 34; 64) 30 (14; 21; 41; 65)
Ordination of “not-to-intubate,” n (%) 26 (13.1) 0
NIV as weaning after ICU, n (%) 8 (4.0) 5 (9.0)
pH at NIV initiation (median)* 7.26 (7.07; 7.21; 7.29; 7.43) 7.24 (7.11; 7.18; 7.28; 7.42)
pCO2 at NIV initiation, kPa (median)* 10.3 (6.1; 9.0; 12.1; 18.4) 9.7 (6.0; 8.8; 11.9; 20.3)
Acute respiratory failure due to 
•  Congestive heart failure, n (%)
•  Thoracic malignancy, n (%)
•  Hypoventilation, n (%)
•  Lung fibrosis, n (%)
•  Pneumonia, n (%)
 
•  13 (6.6)
•  3 (1.5)
•  4¶ (2.0)
•  7 (3.5)
•  2 (1.0)
 
•  0
•  0
•  8¶¶ (14.5)
•  0
•  0
Notes: *(min; 25th percentile; 75th percentile; max); **P , 0.001 (two-sample Wilcoxon rank-sum test); ***of confirmed COPD; ¶(Pickwick 2, muscle dystrophia 1, kyphosis 1); 
¶¶(Pickwick 3, kyphosis 1, cerebral paresis 1, benzodiazepine overdose 3).
Abbreviations: COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 second; n, number; NIV, noninvasive ventilation.
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Figure 1 Survival plot of patients admitted to a respiratory ward (2005–2007) receiving noninvasive ventilation for the first time.
Notes: Total 253 patients (143 female and 110 male). 5-year survival for females 25.7% and males 19.2%. P = 0.25 (logrank).
difference in survival for men and women, although we did 
see a trend towards better long-term 5-year survival in females 
compared to males (25.7% vs 19.2%, P = 0.25 [logrank]). 
Presence of COPD did not affect prognosis, but the trend of 
better long-term 5-year survival in females compared to males 
was maintained (27.2% vs 17.9%, P = 0.083 [logrank]).
The only statistically significant differences found 
between the long-term survivors and patients who died in 
the observation time were age and issue of a not-to-intubate 
order. Survivors had a median age of 66 years compared to 
74 years in nonsurvivors, and the not-to-intubate order was 
associated with 100% mortality. There was no difference in 
registered pH or pCO
2
 between survivors and nonsurvivors 
at initiation of NIV.
Descriptive data of COPD patients versus non-COPD 
patients receiving NIV for the first time are shown in Table 2, 
and supplementary information in Figure 1.
Discussion
Data on long-term survival of patients receiving NIV for the 
first time revealed an expected high 30-day mortality rate, 
considerably higher than that seen in pivotal trials of NIV 
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in COPD,1,2 but in line with other observational audits and 
studies.3,6,7 However, the 5-year survival rate was higher than 
earlier anticipated, which could be due to more stringent 
selection criteria for initiation of NIV, and the fact that the 
study was only conducted in one center, giving patients more 
homogenous treatment. One significant difference between 
survivors and nonsurvivors was age, survivors being, as a 
group, younger than the group of patients who died, but the 
oldest patient (91 years) registered in this study was alive at 
the end of 5 years of observation. We observed a trend of 
better long-term survival in females compared to males, in the 
whole NIV group and especially in patients with COPD, but 
further studies are needed to evaluate confounding variables. 
Unfortunately, the registration of comorbidities was not done 
routinely or stringently, but, in the last couple of years, more 
focus has been made on screening and registration of comor-
bidities in COPD, a benefit for future surveys. Historically, 
males have had a higher exposure of cigarette smoke and 
occupational lung irritants8 and these factors could be con-
tributing to the trend of worse long-term survival.
It is well known that patients entered into clinical trials 
often differ significantly from patients in the usual clinical 
setting. In contrast to randomized controlled studies, this 
patient-based study included a much less selected group of 
patients having more comorbidities presenting with acute 
hypercapnic respiratory failure. Patients were not limited 
to patients with respiratory failure due to exacerbation in 
COPD, and, a priori, one could assume that this would affect 
prognosis. Patients with other diagnoses included patients 
with clearly reversible disorders, such as overdoses of ben-
zodiazepines, but several survivors were patients with other 
less morbid diagnoses than COPD. Despite the disadvantages 
of retrospective and therefore less complete data retrieval 
from records (especially concerning arterial blood analy-
ses), survivors compared to nonsurvivors were similar with 
regards to COPD and, when registered, FEV
1
, pH, and pCO
2
. 
In the non-COPD patients especially severe diseases such as 
congestive heart failure, thoracic malignancy, and end-stage 
fibrosis, were present among nonsurvivors but not at all pres-
ent in survivors. In several of these cases, NIV was given as a 
last treatment option in patients with a not-to-intubate order. 
It seems apparent that patients labeled “not-to-intubate” have 
a particularly poor prognosis and, based, on our findings 
probably did not benefit from the treatment.
The study included all patients initiated in an acute medi-
cal ward setting or a respiratory ward. Unlike two previous 
prospective studies by Berkius et al,6 including 93 COPD 
patients in a multicenter ICU setting, and Harris et al,7 report-
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Figure 2 Survival plot and observation time (years) of COPD patients admitted to a respiratory ward (2005–2007) receiving noninvasive ventilation for the first time.
Notes: Total 216 patients (143 female and 110 male). 5-year survival for females 27.9% and males 17.9%. P = 0.083 (logrank).
Table 2 Survival and observation time of COPD patients versus 
non-COPD patients receiving NIV for the first time
COPD Non-COPD
Patients, n (male/female) 216 (95/121) 37 (14/23)
Age, years (median)* 72 (45; 66; 79; 91) 71 (24; 62; 80; 88)
Mean survival of mortal  
patients, days (median)*
227 (0; 15; 810; 2224) 15 (0; 4; 177; 1302)
Mean observation time  
of survivors, days (median)*
2097 (1707; 1822;  
2509; 2582)
2002 (1609; 1728;  
2412; 2508)
Note: *(min; 25th percentile; 75th percentile; max).
Abbreviations: COPD, chronic obstructive pulmonary disease; NIV, noninvasive 
ventilation.
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ing use of noninvasive ventilation (continuous positive airway 
pressure and bilevel positive airway pressure) in clinical 
practice over 5 years, we have not included patients receiving 
the modality of NIV initiated only in the ICU  setting. Berkius 
et al6 reported survival data (5-year) for COPD patients 
receiving NIV in the ICU (17%), which was lower for patients 
needing intubation (6%). A national British COPD audit from 
2008 on acidosis, NIV, and mortality in hospitalized patients 
with COPD exacerbations, including 232 hospital units and 
9716 patients, showed that 20% of the patients had acidotic 
artery blood analyses at admission.3 NIV treatment in clinical 
practice was given to severely ill patients, many with mixed 
metabolic acidosis. Further, patients fulfilling clinical criteria 
for NIV treatment failed to receive NIV, and others received 
it inappropriately. NIV was also seen used as a ceiling of 
treatment in which efficacy was uncertain.
The primary focus of this present study has not been 
evaluation of the indication for NIV treatment; since 2008, an 
annual national surveillance of patients with COPD (Dansk 
Register for KOL [DrKOL]) has been launched, registration 
practice (International Classification of Diseases [ICD]-10) 
has been reviewed, and audits performed. In Denmark, treat-
ment with NIV was provided to 9% of all COPD patients 
admitted with an exacerbation in 2009 and 10% in 2010 
and 2011.9
Conclusion
Our study confirms that patients with hypercapnic respiratory 
failure are a high-risk group, often with a poor prognosis. 
It casts some doubt as to what is achievable from NIV in a 
non-ICU setting and suggests that regular audits are required 
to ensure that the right patients are offered the right treatment 
when admitted with mild hypercapnic respiratory failure. 
However, the 5-year survival rate was higher than earlier 
anticipated, justifying the broad approach to NIV treatment 
in this setting. The high 30-day mortality rate for all NIV-
initiated patients was higher (29.3%) than for the group of 
patients with COPD (24.3%), and this supports the notion 
that NIV should be dedicated primarily to patients with 
COPD in exacerbation. The 30-day mortality rate for COPD 
patients receiving NIV was similar in an audit from 2010, and 
patients with pH , 7.25 had a worse outcome than patients 
presenting with higher pH at NIV initiation (unpublished 
data). Monitoring of patient outcomes in a real-life setting 
is necessary to ensure optimal selection of patients for NIV 
in a non-ICU setting.
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